90 results match your criteria: "INSERM 1028 and CNRS UMR5292; and Université Claude Bernard Lyon 1 (R.M.)[Affiliation]"

Objective: There is currently scarce data on the electroclinical characteristics of epilepsy associated with synapsin 1 (SYN1) pathogenic variations. We examined clinical and electro-encephalographic (EEG) features in patients with epilepsy and SYN1 variants, with the aim of identifying a distinctive electroclinical pattern.

Methods: In this retrospective multicenter study, we collected and reviewed demographic, genetic, and epilepsy data of 19 male patients with SYN1 variants.

View Article and Find Full Text PDF

The timing of sleep spindles is modulated by the respiratory cycle in humans.

Clin Neurophysiol

October 2024

Lyon Neuroscience Research Centre, INSERM U 1028/CNRS UMR5292, Bron, France; Centre for Sleep Medicine and Respiratory Diseases, Hospices Civils de Lyon, Lyon 1 University, Lyon, France. Electronic address:

Objective: Coupling of sleep spindles with cortical slow waves and hippocampus sharp-waves ripples is crucial for sleep-related memory consolidation. Recent literature evidenced that nasal respiration modulates neural activity in large-scale brain networks. In rodents, this respiratory drive strongly varies according to vigilance states.

View Article and Find Full Text PDF

Diagnostic criteria for optic neuritis in the acute and subacute phase: clinical uses and limitations.

J Neurol

August 2024

Neuro-Ophthalmology Unit, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.

Background: A recent international consensus panel proposed diagnostic criteria for optic neuritis and a new classification. We aimed to investigate the clinical relevance of these diagnostic criteria and classification, in a cohort of patients hospitalized for a suspected diagnosis of optic neuritis.

Methods: We included all patients hospitalized between 2017 and 2022 in our tertiary center for (sub)acute loss of visual acuity suggestive of optic neuritis.

View Article and Find Full Text PDF

Priority setting: women's health topics in multiple sclerosis.

Front Neurol

February 2024

Department of Neurology, Section on Statistical Planning and Analysis, UT Southwestern Medical Center, Dallas, TX, United States.

Background: A scoping review found that most studies on women's health in multiple sclerosis (MS) focused on pregnancy, fetal/neonatal outcomes and sexual dysfunction. Few studies addressed menopause, contraception, gynecologic cancers/cancer screening. However, the perceived relative importance of these knowledge gaps to people living with MS and other partners is unknown.

View Article and Find Full Text PDF

Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis.

Neurol Neuroimmunol Neuroinflamm

March 2024

From the Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation (G.A., P.N., R.M., S.V.), Centre de Ressources, Recherche et Compétence sur la Sclérose en Plaques et Fondation Eugène Devic EDMUS pour la Scléros; Ramsay Santé (G.A., L.G.), Clinique de la Sauvegarde, Lyon; Centre Hospitalier de Valence (L.N.), Service de Neurologie, Valence, France; Sorbonne Université (D.P., C.B.), Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2- Mazarin, Paris, France; OncoNeuroTox Group; Aix Marseille Université (J.P.), APHM, Hôpital de la Timone, Department of Neurology, Marseille; Neurology Department (Y.B., R.D., E.M., T.R.), CRCSEP Paris, Pitié-Salpêtrière Hôpital, APHP; CHU de Caen Normandie (P.B.), Service de Neurologie, Caen; CHU de Toulouse (J.C.), CRC-SEP, Department of Neurology, F-31059 Toulouse Cedex 9; Université Toulouse III, Infinity, INSERM UMR1291 - CNRS UMR5051, F-31024 Toulouse Cedex 3; Polyclinique des Alpes du Sud (Y.D.), Gap, France; Claude Bernard Lyon 1 University (C.F.T.), Lyon Neuroscience Research Center CRNL U1028 UMR 5292, IMPACT F-69500 and Neuro-Ophthalmology Unit, Hospices Civils de Lyon, Neurological Hospital; Centre Hospitalier de Chambéry (C.G.-J.), Service de Neurologie, Chambéry; MeLiS - UCBL-CNRS UMR 5284 - INSERM U1314 (B.J.), Université Claude Bernard Lyon 1; ImmuCare, Institute of Cancerology, Hospices Civils de Lyon, France; Department of Neurology, Hôpital Lyon Sud, Hospices Civils de Lyon; Service de Neurologie (P.K.), Centre Hospitalier de Luxembourg, L-1210 Luxembourg-Ville, Luxembourg; Department of Neurology (A.K.), Lille Catholic University, Lille Catholic Hospitals, FHU PRECISE; CRCSEP Nice (C.L.-F.), UMR2CA-URRIS, Université Nice Côte d'Azur, Neurologie CHU de Nice Pasteur 2; Department of Medical Oncology (A.M.), Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon 1 (R.M.), Villeurbanne; Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (R.M., S.V.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon; and Centre des Neurosciences de Lyon (S.V.), INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques, Lyon, France.

Objectives: Immune checkpoint inhibitors (ICIs) are increasingly used in cancer treatment. Their mechanism of action raises the question of possible exacerbation of preexisting multiple sclerosis (MS). The aim of our study was to assess the risk of increased MS activity, defined by the occurrence of a relapse and/or a new MRI lesion, after ICI initiation.

View Article and Find Full Text PDF

Background: Myelin oligodendrocyte glycoprotein (MOG) IgG seropositivity is a prerequisite for MOG antibody-associated disease (MOGAD) diagnosis. While a significant proportion of patients experience a relapsing disease, there is currently no biomarker predictive of disease course. We aim to determine whether MOG-IgG epitopes can predict a relapsing course in MOGAD patients.

View Article and Find Full Text PDF

Background: Counseling on pregnancy is still challenging, particularly regarding the use of disease-modifying treatments (DMTs). We are lacking long-term outcomes in children exposed to DMTs.

Objectives: This study aimed to set up a French pregnancy registry for women with multiple sclerosis (MS) and related disorders nested within the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort.

View Article and Find Full Text PDF

Fluctuations of consciousness and their rhythmicities have been rarely studied in patients with a disorder of consciousness after acute brain injuries. 24-h assessment of brain (EEG), behaviour (eye-opening), and circadian (clock-controlled hormones secretion from urine) functions was performed in acute brain-injured patients. The distribution, long-term predictability, and rhythmicity (circadian/ultradian) of various EEG features were compared with the initial clinical status, the functional outcome, and the circadian rhythmicities of behaviour and clock-controlled hormones.

View Article and Find Full Text PDF

The role of loudness in vocal intimidation.

J Exp Psychol Gen

February 2024

ENES Bioacoustics Research Lab/Lyon Neuroscience Research Centre (CRNL), CNRS UMR5292, INSERM UMR-S 1028, University of Saint-Etienne.

Across many species, a major function of vocal communication is to convey formidability, with low voice frequencies traditionally considered the main vehicle for projecting large size and aggression. Vocal loudness is often ignored, yet it might explain some puzzling exceptions to this frequency code. Here we demonstrate, through acoustic analyses of over 3,000 human vocalizations and four perceptual experiments, that vocalizers produce low frequencies when attempting to sound large, but loudness is prioritized for displays of strength and aggression.

View Article and Find Full Text PDF

Background And Purpose: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. We aimed to develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs).

Methods: This work was conducted by a multidisciplinary working group using formal consensus methodology.

View Article and Find Full Text PDF

Background: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy.

Objective: To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs).

Methods: This work was conducted by a multidisciplinary working group using formal consensus methodology.

View Article and Find Full Text PDF

Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.

Neurology

July 2023

From the Department of Neurology (S.D., N.C., J.D.S.); Clinical Investigation Center (N.C., J.D.S.), Strasbourg University Hospital; Department of Neurology (B.A.), APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Marseille; Department of Neurology (X.A.), Montpellier University Hospital; Department of Neurology (B.B.), Rouen University Hospital; Department of Neurology CRC-SEP (J.C.), CHU Toulouse; Department of Neurology, CHU Poitiers (J.C.); Department of Neurology (M.C.), CHU de Nice, UR2CA-URRIS, Nice Côte d'Azur University; Department of Neurology (R.D.), Hôpital Fondation Adolphe de Rothschild, Paris; Department of Neurology (F.D.U.R.A.N.D.-D.U.B.I.E.F.), Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique, Hospices Civils de Lyon; Department of Neurology (E.M., C.P.), AP-HP, Pitié-Salpêtrière Hospital, Paris; Department of Neurology (Groupe Hospitalier Pellegrin) (A.R.), Centre Hospitalier Universitaire de Bordeaux; Université de Bordeaux (A.R.), INSERM U1215, Neurocentre Magendie; Department of Neurology (H.Z.), University Hospital of Lille, UFR3S Univ-Lille, Inserm U 1172; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro Inflammation (R.M.), and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Wertheimer, Bron; Centre des Neurosciences de Lyon-FORGETTING Team (R.M.), INSERM 1028 and CNRS UMR5292; and Université Claude Bernard Lyon 1 (R.M.), France.

Background And Objectives: Exit strategies such as de-escalations have not been evaluated for rituximab in patients with neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that they are associated with disease reactivations and aimed to estimate this risk.

Methods: We describe a case series of real-world de-escalations from the French NMOSD registry (NOMADMUS).

View Article and Find Full Text PDF

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.

Neurol Neuroimmunol Neuroinflamm

July 2023

From the Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité Universitaetsmedizin Berlin, Germany; Hospices Civils de Lyon (R.M.), Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro Inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Wertheimer, Bron; Centre des Neurosciences de Lyon-FORGETTING Team (R.M.), INSERM 1028 et CNRS UMR5292; Université Claude Bernard Lyon 1 (R.M.), France; John Radcliff Hospital (J.P.); Clinical Neurology Oxford University (J.P.), Oxford, United Kingdom; Servei de Neurologia-Neuroimmunologia (G.A.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat); Vall d'Hebron Institut de Recerca (G.A.), Vall d'Hebron Hospital Universitari; Universitat Autònoma de Barcelona (G.A.), Spain; Departments of Regional Health Research and Molecular Medicine (N.A.), University of Southern Denmark, Odense, Denmark; Department of Neurology (N.A.), Slagelse Hospital, Denmark; Programs in Neuroscience and Immunology (J.L.B.), Departments of Neurology and Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora; Department of Neurology (B.A.C.C.), UCSF Weill Institute for Neurosciences, University of California San Francisco; Department of Neurology (J.D.S.), Hôpitaux Universitaires de Strasbourg; INSERM U1119 Biopathologie de la Myéline (J.D.S.), Neuroprotection et Stratégies Thérapeutique; Clinical Investigation Center (J.D.S.), Hôpitaux Universitaires de Strasbourg, France; Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine, and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Department of Neurology (H.J.K.), Research Institute and Hospital of National Cancer Center, Goyang, South Korea; Oxford PharmaGenesis Ltd (R.H., L.L.); Department of Neurology (S.H.), Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; Medical Research Center (N.K.), Marrakesh Medical School, Cadi Ayyad University; Neurology Department (N.K.), University Teaching Hospital Mohammed VI, Marrakesh, Morocco; Department of Neurology (I.K.), St Josef-Hospital, Ruhr-University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany; Department of Neurology (S.K.), Graduate School of Medicine, Chiba University, Japan; CIEM MS Research Center (M.L.-P.), Federal University of Minas Gerais, Belo Horizonte, Brazil; John Radcliffe Hospital (M.I.L.), University of Oxford, United Kingdom; KS Hegde Medical Academy Director (L.P.), Center for Advanced Neurological Research, Nitte University, Mangalore, India; Neurology (S.J.P.), Laboratory Medicine and Pathology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN; Department of Neurology and Rare Disease Center (C.Q.), National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, China; Translational Neuroimmunology Group (S.R.), Kids Neuroscience Centre, and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney; Department of Neurology (S.R.), Concord Hospital, Australia; Division of Neurology (D.R.), Department of Medicine, University of Toronto, Ontario, Canada; Neuroimmunology and Multiple Sclerosis Unit (A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona, Spain; School of Medicine (D.K.S.), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics (A.V.-D.), Hadassah-Medical Center, Ein-Kerem, Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Background And Objectives: Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive NMOSD (eculizumab, inebilizumab, and satralizumab), prompting the need to consider best practice therapeutic decision-making for this indication. Our objective was to develop validated statements for the management of AQP4-IgG-seropositive NMOSD, through an evidence-based Delphi consensus process, with a focus on recommendations for eculizumab, inebilizumab, and satralizumab.

View Article and Find Full Text PDF

Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease.

Mult Scler

February 2023

Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro Inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France; INSERM 1028 et CNRS UMR5292, Centre des Neurosciences de Lyon -FORGETTING team, Bron, France/Université Claude Bernard Lyon 1, Villeurbanne, France.

Background And Objective: Myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) frequently initiates during childbearing years. This study investigated the impact of pregnancy and post-partum on MOGAD activity.

Methods: Retrospective analysis of clinical and demographic data from a multicenter French cohort of adult patients with MOGAD.

View Article and Find Full Text PDF

Background: In 2020, the French Multiple Sclerosis (MS) Society (SFSEP) decided to develop a national evidence-based consensus on pregnancy in MS. As neuromyelitis optica spectrum disorders (NMOSD) shares a series of commonalities with MS, but also some significant differences, specific recommendations had to be developed.

Objectives: To establish recommendations on pregnancy in women with NMOSD.

View Article and Find Full Text PDF

Tinnitus is described as an uncomfortable sound or noise heard by an individual in the absence of an external sound source. Treating this phantom perception remains difficult even if drug and nondrug therapies are used to alleviate symptoms. The present case study aimed to investigate whether prism adaptation could induce beneficial aftereffects in a tinnitus sufferer.

View Article and Find Full Text PDF

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Neurology

October 2022

From the CORe (I.R., C.M., T.K.), Department of Medicine, University of Melbourne, Australia; Melbourne MS Centre (I.R., C.M., T.K.), Department of Neurology, Royal Melbourne Hospital, Australia; Rennes, University (E.L.), EHESP, REPERES EA 7449, France; Univ Rennes (E.L.), CHU Rennes, Inserm, CIC 1414 ([Centre d'Investigation Clinique de Rennes]), France; Université de Lyon (R.C.), Université Claude Bernard Lyon 1, France; Hospices Civils de Lyon (R.C.), Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Bron, France; Observatoire Français de La Sclérose en Plaques (R.C.), Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, France; Eugène Devic EDMUS Foundation Against Multiple Sclerosis (R.C.), State-approved Foundation, Bron, France; Department of Neurology and Center of Clinical Neuroscience (D.H., E.K.H.), First Faculty of Medicine, Charles University in Prague and General University Hospital, Czech Republic; Nancy University Hospital (M.D.), Department of Neurology, Nancy, France; Université de Lorraine (M.D.), APEMAC, Nancy, France; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Catania, Italy; Multiple Sclerosis Center (F.P.), University of Catania, Italy; CHU de Strasbourg (J.D.S.), Department of Neurology and Clinical Investigation Center, CIC 1434, INSERM 1434, Strasbourg, France; Hospital Universitario Virgen Macarena (G.I., S.E.), Sevilla, Spain; CHU Pontchaillou (G.E.), CIC1414 INSERM, Rennes, France; CHUM MS Center and Universite de Montreal (A.P., M.G.), Canada; Dokuz Eylul University (S.O.), Konak/Izmir, Turkey; CISSS Chaudière-Appalache (P.G.), Levis, Canada; CHU Lille (H.Z.), CRCSEP Lille, Univ Lille, U1172, France; CHU de Toulouse (J.C.), Hôpital Pierre-Paul Riquet, Department of Neurology, CRC-SEP, France; Département de Neurologie (E.M.), Hôpital Pitié-Salpêtrière, APHP, Paris; CHU de Dijon (T.M.), Department of Neurology, EA4184, France; Department NEUROFARBA (M.P.A.), University of Florence, Italy; CHU de Montpellier (P.L.), MS Unit, France; University of Montpellier (MUSE) (P.L.), France; Division of Neurology (Raed Alroughani), Department of Medicine, Amiri Hospital, Sharq, Kuwait; Department of Neurology (K.B., O.S.), Box Hill Hospital, Melbourne, Australia; Monash University (K.B., O.S.), Melbourne, Australia; Melbourne MS Centre (K.B.), Royal Melbourne Hospital, Australia; The Alfred Hospital (O.S.), Melbourne, Australia; Medical Faculty (M.T.), 19 Mayis University, Samsun, Turkey; CHU de Nantes (D.A.L.), Service de Neurologie & CIC015 INSERM, France; CRTI-Inserm U1064 (D.A.L.), Nantes, France; CHU de Besançon (E.B.), Service de Neurologie 25 030 Besançon, France; Neuro Rive-Sud (F.G.M.), Quebec, Canada; Neurology (C.L.-F.), UR2CA, Centre Hospitalier Universitaire Pasteur2, Université Nice Côte d'Azur, Nice, France; UOC Neurologia (E.C.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; KTU Medical Faculty Farabi Hospital (C.B.), Trabzon, Turkey; School of Medicine and Public Health (J.L.-S.), University Newcastle, Australia; Department of Neurology (J.L.-S.), John Hunter Hospital, Hunter New England Health, Newcastle, Australia; CHU Clermont-Ferrand (Pierre Clavelou), Department of Neurology; Université Clermont Auvergne, Inserm, Neuro-Dol, Clermont-Ferrand, France; Sorbonne Universités (B.S.), UPMC Paris 06, Brain and Spine Institute, ICM, Hôpital de La Pitié Salpêtrière, Inserm UMR S 1127, CNRS UMR 7225, and Department of Neurology, AP-HP, Saint-Antoine Hospital, Paris, France; CSSS Saint-Jérôme (Julie Prevost), Saint-Jerome, Canada; Neurologic Clinic and Policlinic (L.K.), Departments of Medicine and Clinical Research, University Hospital and University of Basel, Switzerland; Aix Marseille Univ (Jean Pelletier), APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, France; Isfahan University of Medical Sciences (V.S.), Iran; Nehme and Therese Tohme Multiple Sclerosis Center (B.I.Y., S.J.K.), American University of Beirut Medical Center, Beirut, Lebanon; Department of Neurology (Oliver Gerlach), Zuyderland Medical Center, Sittard-Geleen, Netherlands; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino (D.L.A.S.), Italy; Cliniques Universitaires Saint-Luc (V.V.P.), Université Catholique de Louvain, Brussels, Belgium; Fondation Rotschild (Olivier Gout), Department of Neurology, Paris, France; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Hôpital de Poissy (O.H.), Department of Neurology, France; Department of Neurology (E.T.), Nimes University Hospital, France; Institut de Génomique Fonctionnelle (E.T.), UMR5203, INSERM 1191, Univ. Montpellier, France; University of Queensland (P.A.M.), Brisbane, Australia; Royal Brisbane and Women's Hospital (P.A.M.), Australia; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; CHU de Rouen (B.B.), Department of Neurology, France; Flinders University (M.S.), Adelaide, Australia; Instituto de Investigación Sanitaria Biodonostia (T.C.-T.), Hospital Universitario Donostia, San Sebastián, Spain; CHU de Reims (S.B.), Department of Neurology, France; Nemocnice Jihlava (Radek Ampapa), Czech Republic; Monash Medical Centre (E.G.B.), Melbourne, Australia; APHP (A.W.), Hôpital Henri Mondor, Department of Neurology, Créteil, France; Austin Health (R.A.M.), Melbourne, Australia; University Hospital Reina Sofia (E.A.-M.), Cordoba, Spain; CHU de La Martinique (Philippe Cabre), Department of Neurology, Fort-de-France, France; Hôpital Sud Francilien (N.H.B.), Department of Neurology, Corbeil Essonnes, France; Department of Neurology (A.V.W., H.B.), The Alfred Hospital, Melbourne, Australia; Central Clinical School (A.V.W., H.B.), Monash University, Melbourne, Australia; Department of Neurology (G.L., L.V.H.), University Hospital Ghent, Belgium; Hospital Germans Trias I Pujol (C.M.R.-T.), Badalona, Spain; CHU La Milétrie (N.M.), Hôpital Jean Bernard, Department of Neurology, Poitiers, France; Liverpool Hospital (S.H.), Sydney, Australia; Hospital de Galdakao-Usansolo (J.L.S.-M.), Spain; Brain and Mind Centre (M.H.B.), Sydney, Australia; CHU Bicêtre (C.L.), Department of Neurology, F-94275 Le Kremlin Bicêtre, France; Westmead Hospital (Steve Vucic), Sydney, Australia; Department of Neurology (Y.S., R.G.), Razi Hospital, Manouba, Tunisia; Department of Neurology (T.C.), Faculty of Medicine, University of Debrecen, Hungary; Hospital Universitari MútuaTerrassa (J.S.), Barcelona, Spain; Groene Hart Ziekenhuis (K.G.), Gouda, Netherlands; Sultan Qaboos University Hospital (A.A.-A.), Al-Khodh, Oman; Universidade Metropolitana de Santos (Y.D.F.), Santos, Brazil; Service de Neurologie (Sandra Vukusic), Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Centre des Neurosciences de Lyon (Sandra Vukusic), Observatoire Français de La Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, France; and Université Claude Bernard Lyon 1 (Sandra Vukusic), Faculté de Médecine Lyon Est, France.

Article Synopsis
  • This study evaluates the rate of disease activity return in multiple sclerosis (MS) patients after they stop using disease-modifying therapy, focusing on relapse rates and factors influencing relapse.
  • A large sample of 14,213 patients showed that relapse rates typically increased within 2 months after stopping treatment, with earlier commencement of new therapy reducing these rates significantly.
  • Factors predicting relapse included having a higher relapse rate prior to stopping therapy, being younger, being female, and having a higher Expanded Disability Status Scale (EDSS) score, with subsequent therapy reducing both relapse risk and disability progression.
View Article and Find Full Text PDF

["Diagnosis of multiple sclerosis, diagnostic criteria and contribution of imaging to diagnosis"].

Rev Prat

April 2022

"Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, centre de recherche, ressource et compétence sur la sclérose en plaques, et fondation Eugène-Devic EDMUS, hôpital neurologique Pierre-Wertheimer, Hospices civils de Lyon, France".

"Diagnosis of multiple sclerosis, diagnostic criteria and contribution of imaging to diagnosis The diagnosis of multiple sclerosis is a probabilistic diagnosis, based on a combination of clinical and imaging evidence. The current diagnostic criteria are the MacDonald 2017 criteria; they allow for a safer and earlier diagnosis and minimize the risk of overdiagnosis. These criteria should only be used in patients with a subacute or progressive clinical presentation already highly suggestive of MSs.

View Article and Find Full Text PDF

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

BMC Med Res Methodol

May 2022

Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes, France.

Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies.

View Article and Find Full Text PDF

Using acoustics and artificial intelligence to monitor pollination by insects and tree use by woodpeckers.

Sci Total Environ

September 2022

Institut de Systématique, Évolution, Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Université des Antilles, 57 rue Cuvier, 75005 Paris, France. Electronic address:

The collection and interpretation of field data is a prerequisite for informed conservation in protected environments. Although several techniques, including camera trapping and passive acoustic monitoring, have been developed to estimate the presence of animal species, very few attempts have been made to monitor ecological functions. Pollination by insects and wood use, including tree related foraging and intraspecific communication, by woodpeckers are key functions that need to be assessed in order to better understand and preserve forest ecosystems within the context of climate change.

View Article and Find Full Text PDF

Background: Neuromyelitis optica spectrum disorder (NMOSD) attacks require an urgent probabilistic anti-inflammatory therapeutic strategy. As inadequately treated attacks result in disability, there is a need to identify the optimal attack-treatment regimen. Our study aimed to identify predictors of outcome after a first attack in patients with an NMOSD presentation and propose the best treatment strategy.

View Article and Find Full Text PDF

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies.

View Article and Find Full Text PDF

Women's Health in Multiple Sclerosis: A Scoping Review.

Front Neurol

January 2022

Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

Background: Women with multiple sclerosis (MS) may face challenges related to managing reproduction, pregnancy, and menopause while simultaneously managing their disease. The purpose of this scoping review was to map the literature broadly related to topics relevant to women's health in MS to inform the clinical and research communities about the existing types and sources of evidence and knowledge gaps. Apart from coverage of topics within the field of women's health, we were interested in potential gaps related to geographic and racial and ethnic diversity.

View Article and Find Full Text PDF

Social pressure drives "conversational rules" in great apes.

Biol Rev Camb Philos Soc

April 2022

Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie animale et humaine) - UMR 6552, 263 avenue du Général Leclerc, Rennes, 35042, France.

In the last decade, two hypotheses, one on the evolution of animal vocal communication in general and the other on the origins of human language, have gained ground. The first hypothesis argues that the complexity of communication co-evolved with the complexity of sociality. Species forming larger groups with complex social networks have more elaborate vocal repertoires.

View Article and Find Full Text PDF

Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study.

Neurology

February 2022

From Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (A.G.-D., R.M.), Service d'Imagerie Médicale (R.A.), and Centre de Référence des Syndromes Neurologiques Paranéoplasiques et Encéphalites Auto-immunes (V.R., B.J., S.M.-C., A.V., G.P., J.H.), Hôpital Neurologique Pierre Wertheimer, and Service de Neurologie Pédiatrique, Hôpital Femme Mère Enfant (C.F.), Hospices Civils de Lyon, Lyon/Bron; Institut NeuroMyoGène (V.R., B.J., S.M.-C., A.V., G.P., J.H.), INSERM 1217 et CNRS UMR5310; Université Claude Bernard Lyon 1 (V.R., B.J., S.M.-C., A.V., G.P., J.H.), Faculté de Médecine Lyon Est; Centre de Recherche en Neurosciences de Lyon (A.R., R.M.), INSERM 1028 et CNRS UMR5292, France; Stanford University Center for Sleep Sciences and Medicine (A.A.), Palo Alto, CA; Service de Neurologie Cognitive, Épilepsie, Sommeil et Mouvements Anormaux (M. Benaiteau) and Service de Neurologie Inflammatoire et Neuro-oncologie (F.R., J.C.), Hôpital Pierre-Paul Riquet, Hôpitaux de Toulouse; Service de Neuropédiatrie (K.D.), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre; Service de Neurologie (T.d.B.), Hôpital Delafontaine, Centre Hospitalier de Saint-Denis; Service de Neurologie, Hôpital de Hautepierre (L.K.), Hôpitaux Universitaires de Strasbourg; Service de Neurologie (P.K.), Centre Hospitalier de Luxembourg; Service de Neurologie (F.S.) and Service de Médecine Interne (B.B.), Hôpitaux Civils de Colmar; Unité INSERM U-1118 (F.S.), Faculté de Médecine, Université de Strasbourg; Service de Médecine Interne (R.G.), Hôpital d'Instruction des Armées Legouest, Metz; Service de Neurologie (J.B.) and Service de Médecine Interne et Immunologie Clinique (A.B.), Centre Hospitalier Régional Universitaire de Tours; Service de Neurologie et Maladies Neuromusculaires (F.D.), Groupe Hospitalier Pellegrin, Hôpitaux de Bordeaux; Service de Médecine Intensive et Réanimation (N.I.), Hôpital Saint André, Bordeaux; Service de Neurologie (E.-C.R.), Hôpital Sainte Musse, Centre Hospitalier Intercommunal de Toulon; Service de Neurologie (M.G.), Hôpital Emile Muller, Mulhouse; Service de Neurologie (A.D.), Centre Hospitalier de Perpignan; Pôle Cardio-vasculaire et Métabolique (J.L.D.), Centre Hospitalier de Cayenne; Service de Neurologie (L.H.), Hôpital Central, CHRU Nancy; Service de Neurologie (A.-L.K.), CHU de Saint-Etienne, Saint-Priest-en-Jarez; Service de Neuropédiatrie (M.P.), Site Mère Enfant, CHU Martinique, Fort-de-France; Service de Neurologie (E.C.), CHU Gabriel-Montpied, CHU de Clermont-Ferrand; Service de Neurologie (A.L.), Hôpital d'Instruction des Armées Clermont-Tonnerre, Brest; Service de Neurologie (E.M.), Hôpital Fondation Adolphe de Rothschild, Paris; Service de Neurologie et Laboratoire de Neurosciences Fonctionnelles et Pathologies (D.A.), Centre Hospitalier Universitaire d'Amiens et Université de Picardie Jules Verne, Amiens; Service de Neurologie (P.D.), Hôpital Laënnec, Centre Hospitalier de Cornouaille, Quimper; Service de Neurologie (G.M.), Centre Hospitalier Universitaire de La Réunion, Saint Pierre; Service de Neurologie (C.D.), Hôpital Roger Salengro, Centre Hospitalier Universitaire de Lille; Service de Neurologie (V.B.), Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice; Service de Médecine Interne et Maladies Infectieuses (Q.B.), Centre Hospitalier d'Angoulême; Service de Neurologie (I.G.-C.) and Service de Réanimation (G.R.), Centre Hospitalier de Saint-Brieuc; Service de Médecine Polyvalente et de Médecine Interne (D.M.-T.), Centre Hospitalier Le Mans; Service de Neurologie (M. Bonnan), Centre Hospitalier de Pau; and Service de Neurologie/UNV (T.T.), Centre Hospitalier de Saintonge, Saintes, France.

Background And Objectives: To report the clinical, biological, and imaging features and clinical course of a French cohort of patients with glial fibrillary acidic protein (GFAP) autoantibodies.

Methods: We retrospectively included all patients who tested positive for GFAP antibodies in the CSF by immunohistochemistry and confirmed by cell-based assay using cells expressing human GFAPα since 2017 from 2 French referral centers.

Results: We identified 46 patients with GFAP antibodies.

View Article and Find Full Text PDF